Bulevirtide: First Approval

GS-13-Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection

(2019) Heiner Wedemeyer et al.   JOURNAL OF HEPATOLOGY

Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection

(2018) H. Wedemeyer et al.   JOURNAL OF HEPATOLOGY

First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B

(2016) Antje Blank et al.   JOURNAL OF HEPATOLOGY

Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study

(2016) Pavel Bogomolov et al.   JOURNAL OF HEPATOLOGY

Quantitative bile acid profiling by liquid chromatography quadrupole time-of-flight mass spectrometry: monitoring hepatitis B therapy by a novel Na+-taurocholate cotransporting polypeptide inhibitor

(2015) Mathias Haag et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY

The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus

(2012) Tassilo Volz et al.   JOURNAL OF HEPATOLOGY